475 reports of this reaction
2.5% of all ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR reports
#9 most reported adverse reaction
CYSTIC FIBROSIS is the #9 most commonly reported adverse reaction for ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR, manufactured by Vertex Pharmaceuticals Incorporated. There are 475 FDA adverse event reports linking ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR to CYSTIC FIBROSIS. This represents approximately 2.5% of all 19,269 adverse event reports for this drug.
Patients taking ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR who experience cystic fibrosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CYSTIC FIBROSIS is a less commonly reported adverse event for ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR, but still significant enough to appear in the safety profile.
In addition to cystic fibrosis, the following adverse reactions have been reported for ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR:
The following drugs have also been linked to cystic fibrosis in FDA adverse event reports:
CYSTIC FIBROSIS has been reported as an adverse event in 475 FDA reports for ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR. This does not prove causation, but indicates an association observed in post-market surveillance data.
CYSTIC FIBROSIS accounts for approximately 2.5% of all adverse event reports for ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR, making it a notable side effect.
If you experience cystic fibrosis while taking ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.